MICROBIX BIOSYSTEMS INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.325 CAD | +1.56% |
|
-2.99% | -16.67% |
| May. 15 | Microbix Biosystems Up More Than 10% As Q2 Profit Grows On Higher Revenues; Says Stage Set For Record FY | MT |
| May. 15 | Transcript : Microbix Biosystems Inc., Q2 2024 Earnings Call, May 15, 2024 |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -17.95% | 32.07M | - | - | |
| +67.53% | 63.85B | B- | ||
| -0.77% | 41.83B | B | ||
| +44.47% | 40.65B | A | ||
| -10.72% | 27.12B | C | ||
| +13.30% | 26.52B | B- | ||
| -22.79% | 18.69B | B | ||
| +4.70% | 12.73B | B+ | ||
| +24.10% | 12.11B | B+ | ||
| +27.41% | 12.07B | C+ |
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
-
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MBX Stock
- Ratings Microbix Biosystems Inc.
